Home / Recalls / Apollo Care, LLC / D-0754-2026

D-0754-2026 Class II Ongoing

Recalled by Apollo Care, LLC — Columbia, MO

FDA drug recall D-0754-2026 was initiated by Apollo Care, LLC on July 29, 2026 and is designated Class II. Reason for recall: Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material The recall status is ongoing. Affected quantity: 250 vials..

Recall Details

Product Type
Drugs
Report Date
August 19, 2026
Initiation Date
July 29, 2026
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
250 vials.

Product Description

SEMAGLUTIDE 5mg (1mg/mL), Glycine 25 mg (5mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202.NDC 71170-712-03

Reason for Recall

Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material

Distribution Pattern

Nationwide within the U.S

Code Information

Lot: AC-017272, Exp. 12/12/2026.

Other recalls by Apollo Care, LLC

  • D-0747-2026 Class II — SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcut (July 29, 2026)
  • D-0749-2026 Class II — SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Sub (July 29, 2026)
  • D-0755-2026 Class II — SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose V (July 29, 2026)
  • D-0751-2026 Class II — SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutan (July 29, 2026)
  • D-0750-2026 Class II — SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcut (July 29, 2026)
  • D-0748-2026 Class II — SEMAGLUTIDE 2.25MG (0.9 mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Sub (July 29, 2026)
  • D-0756-2026 Class II — SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, (July 29, 2026)
  • D-0752-2026 Class II — SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, Rx Only, For Subcut (July 29, 2026)
  • D-0757-2026 Class II — SEMAGLUTIDE 20mg (5mg/mL), Glycine 20 mg (5mg/mL), 4 mL Sterile Multi-Dose Vial, (July 29, 2026)
  • D-0753-2026 Class II — SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose (July 29, 2026)

FDA data resources